Collegium Pharmaceutical, Inc. Interest Expense Nonoperating
Collegium Pharmaceutical, Inc. (COLL) reported Interest Expense Nonoperating of $19.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $19.52M, a 4.61% decline year-over-year.
- Collegium Pharmaceutical, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $15.86M, a 23.70% decline year-over-year.
- Collegium Pharmaceutical, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $19.29M, a 14.84% decline year-over-year.
- Collegium Pharmaceutical, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $21.77M, a 18.34% increase year-over-year.
- Collegium Pharmaceutical, Inc. interest expense nonoperating for fiscal 2025 was $82.31M, a 11.27% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. interest expense nonoperating for fiscal 2024 was $73.97M, a 11.24% decline from fiscal 2023.
- Collegium Pharmaceutical, Inc. interest expense nonoperating for fiscal 2023 was $83.34M, a 31.84% increase from fiscal 2022.
- Collegium Pharmaceutical, Inc. interest expense nonoperating for fiscal 2022 was $63.21M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.52M 10-Q · filed 2026-08-06 | $35.38M 10-Q · filed 2026-08-06 | $54.67M derived: sum of 3 quarters · filed 2026-08-06 | $76.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.86M 10-Q · filed 2026-05-07 | $35.15M derived: sum of 2 quarters · filed 2026-05-07 | $56.92M derived: sum of 3 quarters · filed 2026-05-07 | $77.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $19.29M 10-K · filed 2026-02-26 | $41.06M derived: sum of 2 quarters · filed 2026-02-26 | $61.52M derived: sum of 3 quarters · filed 2026-08-06 | $82.31M 10-K · filed 2026-02-26 |
| 2025-09-30 | $21.77M 10-K · filed 2026-02-26 | $42.23M derived: sum of 2 quarters · filed 2026-08-06 | $63.02M 10-Q · filed 2025-11-06 | $85.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $20.46M 10-Q · filed 2026-08-06 | $41.25M 10-Q · filed 2026-08-06 | $63.91M derived: sum of 3 quarters · filed 2026-08-06 | $82.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $20.79M 10-Q · filed 2026-05-07 | $43.44M derived: sum of 2 quarters · filed 2026-05-07 | $61.84M derived: sum of 3 quarters · filed 2026-05-07 | $77.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $22.65M 10-K · filed 2026-02-26 | $41.05M derived: sum of 2 quarters · filed 2026-02-26 | $56.63M derived: sum of 3 quarters · filed 2026-02-26 | $73.97M 10-K · filed 2026-02-26 |
| 2024-09-30 | $18.39M 10-K · filed 2026-02-26 | $33.98M derived: sum of 2 quarters · filed 2026-02-26 | $51.32M 10-Q · filed 2025-11-06 | $70.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $15.59M 10-K · filed 2026-02-26 | $32.93M 10-Q · filed 2025-08-07 | $52.21M derived: sum of 3 quarters · filed 2026-02-26 | $72.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $17.34M 10-K · filed 2026-02-26 | $36.62M derived: sum of 2 quarters · filed 2026-02-26 | $57.39M derived: sum of 3 quarters · filed 2026-02-26 | $79.25M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $19.28M 10-K · filed 2025-02-27 | $40.05M derived: sum of 2 quarters · filed 2025-02-27 | $61.91M derived: sum of 3 quarters · filed 2025-02-27 | $83.34M 10-K · filed 2026-02-26 |
| 2023-09-30 | $20.77M 10-K · filed 2025-02-27 | $42.63M derived: sum of 2 quarters · filed 2025-02-27 | $64.06M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $21.86M 10-K · filed 2025-02-27 | $43.29M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $21.43M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $63.21M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |